Title: Statin Use and the Risk of Hepatocellular Carcinoma Among Patients With Chronic
Hepatitis B: An Emulated Target Trial Using Longitudinal Nationwide Population Cohort Data
Version: 1 Date: 23 Aug 2023
Reviewer:  Li-Hsuan Wang
Reviewer's report:
Overall, the content of the manuscript is very interesting, and the author addresses an important
issue. It is generally well-done. However, a few suggestions described below needs to be added
in detail:
1. Why author have to exclude patients have diagnosis on myocardial infarction, heart failure,
coronary heart disease, or revascularization? Are these diseases HCC risks?
2. Author how to choice concomitant medications? Why author not consider metformin effect?
3. In discussion section, author illustrate the studied cohort patients receiving antiviral therapy
proportion was very low (1%) and with relatively low HCC incidence rates (0.2~0.3 per 1,000
person-years). Does this condition meet the clinical situation? Author how to interpret result and
needs to be described in detail
Title: Statin Use and the Risk of Hepatocellular Carcinoma Among Patients With Chronic
Hepatitis B: An Emulated Target Trial Using Longitudinal Nationwide Population Cohort Data
Version: 1 Date: 23 Aug 2023
Reviewer:  Li-Hsuan Wang
Reviewer's report:
Overall, the content of the manuscript is very interesting, and the author addresses an important
issue. It is generally well-done. However, a few suggestions described below needs to be added
in detail:
1. Why author have to exclude patients have diagnosis on myocardial infarction, heart failure,
coronary heart disease, or revascularization? Are these diseases HCC risks?
2. Author how to choice concomitant medications? Why author not consider metformin effect?
3. In discussion section, author illustrate the studied cohort patients receiving antiviral therapy
proportion was very low (1%) and with relatively low HCC incidence rates (0.2~0.3 per 1,000
person-years). Does this condition meet the clinical situation? Author how to interpret result and
needs to be described in detail
Please review this paper.
user
Title: Statin Use and the Risk of Hepatocellular Carcinoma Among Patients With Chronic
Hepatitis B: An Emulated Target Trial Using Longitudinal Nationwide Population Cohort Data
Version: 1 Date: 23 Aug 2023
Reviewer:  Li-Hsuan Wang
Reviewer's report:
Overall, the content of the manuscript is very interesting, and the author addresses an important
issue. It is generally well-done. However, a few suggestions described below needs to be added
in detail:
1. Why author have to exclude patients have diagnosis on myocardial infarction, heart failure,
coronary heart disease, or revascularization? Are these diseases HCC risks?
2. Author how to choice concomitant medications? Why author not consider metformin effect?
3. In discussion section, author illustrate the studied cohort patients receiving antiviral therapy
proportion was very low (1%) and with relatively low HCC incidence rates (0.2~0.3 per 1,000
person-years). Does this condition meet the clinical situation? Author how to interpret result and
needs to be described in detail
assistant